Differential effect of Fingolimod and Natalizumab treatments on B lymphocyte subpopulations and humoral responses in patients with relapsing remitting multiple sclerosis by Μπουλογιάννη, Ιουλία
        
 
Differential effect of Fingolimod and 
Natalizumab treatments on B lymphocyte 
subpopulations and humoral responses in 
patients with relapsing remitting multiple 
sclerosis 
Διαφορική επίδραση των Fingolimod και Natalizumab θεραπειών στους 
υποπληθυσμούς Β κυττάρων και στις χυμικές αποκρίσεις ασθενών με 
RRMS 
 
  
      
   Ioulia Boulogianni  
     Department of Μolecular Μedicine , Eberhard Karls University of  Tübingen, Germany  
     Department of Biochemistry & Biotechnology, University of Thessaly, Greece 
     Spring 2014, Tübingen, Germany  
 
  
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 10:19:01 EET - 137.108.70.7
 BOULOGIANNI IOULIA            1 
 
Examiners-Thesis advisors 
 
 Dr. Felix Bischof : private lecturer (PD) of 
neurosciences , department of molecular medicine , 
Karls Eberhard university of Tübingen, Germany 
 
 
 Anna Maria Psarra : assistant professor of 
biochemistry, department of biochemistry and 
biotechnology, university of Thessaly  
 
 
 Dimitrios Leonidas : associate professor of 
biochemistry, department of biochemistry and 
biotechnology, university of Thessaly  
  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 10:19:01 EET - 137.108.70.7
 BOULOGIANNI IOULIA            2 
 
INDEX 
ABSTRACT                                                                                          4 
 
INTODUCTION                                                                                   5 
 
AIM OF THESIS                                                                                 14 
 
MATERLIAS AND METHODS                                                           15 
 
RESULTS                                                                                            18 
 
DISCUSSION                                                                                      31 
 
PERSPECTIVES                                                                                  38 
 
ACKNOWLEDGMENTS                                                                    38 
 
REFERENCES                                                                                     39 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 10:19:01 EET - 137.108.70.7
 BOULOGIANNI IOULIA            3 
 
Περίληψη 
 
Η πολλαπλή σκλήρυνση (ή σκλήρυνση κατά πλάκας) είναι μια χρόνια αυτό-άνοση 
ασθένεια, της οποίας ο ακριβής μηχανισμός  παθογένειας της δεν  είναι πλήρως 
κατανοητός. Βιβλιογραφικά δεδομένα αποκαλύπτουν  την εμπλοκή κυττάρων τόσο 
του ανοσοποιητικού όσο και του νευρικού συστήματος στην εκδήλωση της 
παθογένειας της νόσου. Όσο αφορά τα κύτταρα του ανοσοποιητικού, πρόσφατες 
μελέτες υποδηλώνουν ότι πέρα από την αρχικά διαπιστωμένη εμπλοκή των Τ 
κυττάρων στην εκδήλωση της παθογένειας της νόσου και τα Β κύτταρα φαίνονται να 
σχετίζονται  με αυτήν. Στην συγκεκριμένη μελέτη, αξιολογήθηκε η επίδραση δύο 
φαρμακευτικών αγωγών, Natalizumab και Fingolimod, στα επίπεδα των υπό-
πληθυσμών των Β λεμφοκυττάρων που εντοπίζονται στο αίμα ασθενών με 
σκλήρυνση κατά πλάκας σε σχέση με τα αντίστοιχα επίπεδα υγειών ατόμων. Σκοπός 
της μελέτης αυτής είναι να ενισχύσει την άποψη που θέλει τα Β λεμφοκύτταρα ως 
κρίσιμους ρυθμιστές της πολλαπλής σκλήρυνσης. Συγκεκριμένα, εξετάστηκαν τα 
επίπεδα των παρθένων Β κυττάρων  (CD3- CD19+CD27-), των Β κυττάρων μνήμης 
(CD3- CD19+CD27+ CD20+) και των πλασματοκυττάρων (CD3- CD19+CD27+ CD20-) 
τόσο ασθενών με RRMS (Relapsing Remitting Multiple Sclerosis)  όσο και  υγειών 
ατόμων. Τα αποτελέσματα έδειξαν, ότι οι ασθενείς που τους χορηγήθηκε Fingolimod  
είχαν σημαντικά μειωμένα επίπεδα  Β κυττάρων (CD3- CD19+) στο αίμα τους σε 
σύγκριση με αυτούς που λάμβαναν Natalizumab (P < 0.001). Επίσης , τόσο η 
χορήγηση του Natalizumab όσο και του Fingolimod προκαλεί μείωση στα επίπεδα των 
πλασματοκυττάρων σε σύγκριση με υγιείς (P < 0.001), παρόλο που η μείωση είναι 
πιο αξιοσημείωτη στο αίμα ασθενών που λαμβάνουν Natalizumab (P=0.0098). 
Επιπλέον η χορήγηση του Fingolimod οδηγεί σε δραματική μείωση των ΙgG+ 
πλασματοκυττάρων σε σύγκριση με τα άλλα δυο γκρουπ ατόμων. Τα αποτελέσματα 
αυτά, υποδεικνύουν διαφορές στην επίδραση των δυο θεραπειών στους υπό-
πληθυσμούς των Β κυττάρων , με την μεγαλύτερη μείωση στα επίπεδα των Β 
λεμφοκυττάρων μετά την πρόσληψη του Fingolimod και την σημαντική μείωση στα 
επίπεδα των πλασματοκυττάρων στο αίμα ασθενών που λαμβάνουν Natalizumab. 
Σπουδαίο εύρημα αποτελεί ότι το Fingolimod προκαλεί δραματική μείωση στα IgG+ 
πλασματοκύτταρα ασθενών. Συμπερασματικά, οι θεραπείες αυτές επηρεάζουν 
διαφορετικά τα επίπεδα των υπό-πληθυσμών των Β κυττάρων. Η ένδειξη αυτήν 
μπορεί να αποτελέσει έναυσμα για την βελτίωση των υπάρχοντών θεραπειών και την 
εφαρμογή μιας εξιδανικευμένης θεραπείας ανάλογα με τον εκάστοτε ασθενή.  
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Abstract  
Controversy has arisen about the etiology of Multiple sclerosis (MS) pathogenesis. 
Although it is originally described as being T cell-based autoimmune disease, some 
studies have recently reported that B cells have potential role in the pathogenesis of 
MS. In the present study, we evaluated the effects of Natalizumab (N= 9) and 
Fingolimod (N=9) treatments on the frequency of B lymphocyte subpopulations in the 
peripheral blood of patients with relapsing remitting multiple sclerosis (RRMS), providing 
insights of the important role of B cells in immune- pathogenesis of MS. Healthy 
people (N=9) were considered as control group. Particularly, differences in 
populations of naïve (CD3- CD19+CD27-)-, memory B cells (CD3- CD19+CD27+ CD20+) 
and plasmablasts (CD3- CD19+CD27+ CD20-) were evaluated in control group and 
groups of patients treated with Natalizumab or Fingolimod. The results of this survey 
showed that in contrast to Natalizumab therapy, Fingolimod treatment significantly 
reduced the frequency of CD3-CD19+ B cells in RRMS patients (P < 0.001). Both 
Fingolimod and Natalizumab treatments markedly reduced the rate of B cell 
subpopulation, plasma cells (CD20-CD27+ cells) in comparison with Healthy controls 
(P < 0.001), but the effect of Natalizumab was more dramatic than Fingolimod 
(P=0.0098). In addition, the RRMS patients with Fingolimod therapy showed essential 
reduction in the percentage of IgG+ cells inside of CD3-CD19+CD20-CD27+ terminally 
differentiated B lymphocytes. The results of present study demonstrate that both 
Fingolimod and Natalizumab therapies have considerable effects on the frequency of 
B Cells and B cell populations, with Fingolimod to be more effective in the reduction 
of B cells (CD3-CD19+) and Natalizumab to be much more conducive in the reduction 
of plasma cell (CD20-CD27+) subpopulation. The finding that Fingolimod has 
dramatically reduced the percentage of IgG+ B cells in the terminally differentiated B 
cells is the new finding that we present in this research. It seems that MS drugs 
differentially affect the distribution of B lymphocyte subsets. These findings can 
contribute to better understanding of MS pathology, bringing some insights for design 
of individual treatments of MS patients.  
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Introduction 
Multiple sclerosis  
Multiple sclerosis (MS), in essence, is a chronic inflammatory disease that affects over 1 
million people worldwide (Heather L Wilson et al. 2012). Except of an inflammatory disorder, 
multiple sclerosis is one of the most serious neurological disorders, which damages the 
insulating covers of nerve cells in the brain and spinal cord.  
 
1. Sagittal T1-weighted MRI depicts multiple hypointense lesions in the corpus callosum; this finding 
is characteristic of multiple sclerosis. 2. Axial T2-weighted MRI in a patient with multiple sclerosis 
demonstrates numerous white matter plaques in a callosal and pericallosal white matter 
distribution. (Brain imaging in Multiple sclerosis) 
 
This demyelinating disease is presented most common in individuals aged 20–40 years 
and is associated with marked physical and cognitive disabilities, including mental and 
mood disorders and a shortened life span as well. (Heather L Wilson et al. 2012 ) 
 
The spread in the clinical picture of MS has traditionally been seen as a strong evidence 
for heterogeneity of this disorder. MS is presented with diverse forms (relapsing 
forms, progressive forms). The classification of MS phenotypes based on 
characterization of MS lesions (MS plaques)  (Gregory F. Wu et al. 2011) .The lesions 
mostly affect the white matter in the optic nerve, brain stem, basal ganglia, and spinal 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 10:19:01 EET - 137.108.70.7
 BOULOGIANNI IOULIA            6 
 
cord, or areas of the white matter close to the lateral ventricles.  The function of white 
matter cells is to transport signals between grey matter areas. 
 
Especially as a pathologic hallmark of MS used to be plaques of inflammatory myelin 
breakdown within the CNS (Gregory F. Wu et al. 2011). These plaques are created due 
to the myelin destruction. The most common pattern of these plaques involves the 
presence of Abs, components of completment, T cells and macrophages. In this sense, 
MS plaque formation is a combination of function of innate and adaptive immune 
cells. Furthermore, MS is associated with the loss of oligodendrocytes, the cells 
responsible for creating and maintaining a fatty layer—known as the myelin sheath—
which helps the neurons carry electrical signals (action potentials). This results in a 
thinning or complete loss of myelin and, as the disease advances, the breakdown of 
the axons of neurons. 
 
Usually, MS plaque classification is based on progression (stages) of inflammatory 
destruction. Accordingly, acute, chronic active, and chronic silent lesions are thought 
to occur along a continuous timeline. The majority of MS patients initially present with 
subacute attacks, with symptoms and signs referable to the central nervous system 
(CNS) – defined as a clinically isolated syndrome (CIS). When the attack is followed by 
a complete or partial remission which is then followed by another attack(s), often 
focused in a different location in the CNS and possibly of higher intensity, the disease 
course is defined as relapsing and remitting MS (RRMS). Patients who present with a 
gradually progressive course without a well-defined initial attack are presenting with 
primary progressive MS (PPMS). Secondary progressive MS (SPMS) is characterized 
by CIS or RRMS followed by progressive clinical worsening over time, generally 3 years 
or more after the onset of disease. (Heather L Wilson et al. 2012).  
Neuro-immune pathogenesis of multiple sclerosis 
This complicated autoimmune disorder has yet an unknown etiology. While the cause 
is not so clear, the underlying mechanism is thought to be either destruction by the 
immune system or failure of the myelin-producing cells (oligodendrocytes- 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 10:19:01 EET - 137.108.70.7
 BOULOGIANNI IOULIA            7 
 
remyelination). Proposed causes for this include genetics and environmental factors 
such as infections. In any case, the main constituents of immune cells seems to be 
pathogenic T lymphocytes that are thought to underlie MS immune pathology.  
 
It is well known that MS   is caused by an autoimmune response to self-antigens in a 
genetically susceptible individual induced by gene-environment-infectious  
interactions.  Principally, the demyelination and axonal lesion in MS patients mediated 
by T cells, especially by CD4+ T cells with a proinflammatory T helper (Th) 1 and Th17 
subsets. 
 
To begin with, the main function of the immune system is defense against external 
and internal antigens. Those of external origin usually belong to microorganisms and 
the internal antigens arise from malignant cells of organisms, after their destruction 
of replication mechanisms. Thus, it’s clearly understandable that immune system 
except of its important role in attacking external ‘’enemies’’, has a different but 
extremely important function that is prevention of autoreactive T and B cells 
activation. This activation, probably, will be a threat for the organism because in some 
cases could trigger autoimmune diseases, like MS.  In order to be avoided this negative 
effect, there is a regulatory mechanism presented as recessive tolerance (RT).  This 
mechanism based on deletion of autoreactive T and B cells in the thymus or in a bone 
marrow during the process of their maturation in these primary lymphoid organs. 
Sometimes the mechanisms of RT are not efficient to prevent all the autoreactive   
lymphocytes, a part of them escape their apoptosis, enter to periphery and finally 
reach the regions where are located the secondary lymphoid organs. Here, there is a 
high possibility of activation of autoreactive lymphocytes, if they come up against 
auto-antigens, cross reactive-antigens or in case of dysregulation of the immune 
system. This activation can cause a cascade of immune reactions that maybe induce 
autoimmunity.  
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Contribution of B cells and humoral responses in MS pathogenesis 
 
During the past years, there is continuous attempt to clarify the role of immune cells 
in MS pathogenesis. T cells and mostly CD4+ helper cells have been considered as a 
‘’key’’ in MS pathogenesis. This hypothesis is further supported by the activated T 
lymphocytes in MS plaques. Despite the thought that MS being T cell driven disease, 
an emerging evidence comes from recent studies of EAE models and implicates the 
contribution of B cells and humoral responses in the pathology of MS. It is already 
known that an increased intrathecal production of immunoglobulins (Ig) in the CSF is 
remarked in more than 90% of Multiple Sclerosis patients (Kabat et al. 1948). The Igs 
which are principally produced, are involve IgG, IgA, IgD and IgM (Walsh et al. 1985,  
Sharief and Thompson  1991). Clonally expanded B cells exist in the central nervous 
system (CNS) and cerebrospinal fluid (CSF) and follicle like aggregates can be found to 
MS brain, suggesting to an antigen-driven B cells response.  Evidence suggests that 
treatments with antibodies (like anti-CD20, acts on B cells compartment by depleting 
the B cells positive for the CD20) based on targeting on B cells subtypes are effectual 
in RRMS, confirming the pathogenic role of B cells in MS (G. Disanto et al. 2012). 
Likewise, it has been observed that increased concentrations of Abs in CSF of patients 
relate to episodes of MS worsening (Olsson and Link, 1973). Taken together, these 
findings indicate a B cell – driven pathology of MS, suggesting that the underlying 
mechanisms of MS are heterogeneous.  
 
In spite of the great implication of antibodies in MS disorder, they cannot engender 
alone CNS inflammation. Remarkably, when the blood-brain-barrier (BBB) is broken 
by T cell mediated response, plasma cells and their antibodies may worsen the 
progress of disease. The implication of T cells in the onset of disorder is referred in the 
literature as a “first hit” while the implication of antibodies is called “second hit”. 
(Markus Krumbholz et al. 2012) 
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For the determination of B cell participation in MS pathology, is useful to refer the 
basics of B cell development. First stage in the B cell maturation to pro- and pre- B 
cells take place in the bone marrow. The second lymphoid organs is the place where 
the immature naïve B cells develop into mature naïve ones. The B cell tolerance is 
achieved with different mechanisms analogous to the process while auto-reactive T 
cells are eliminated. The facts that naïve B cells encounter their antigens in the second 
lymphoid organs drive them to activation and proliferation. Part of these activated B 
cells migrate out of lymph follicles to become short lived plasma blasts, producing 
antibodies during a lifespan limited to 1-3 days. The rest antigen-activated naïve B 
cells follow an alternative path of development in germinal center reaction (GCs). 
There B cells (centroblasts) undergo processes like selection, somatic hypermutation 
, class switch and affinity maturation , which in a combination lead to production of 
memory B cells. Plasmablasts and plasma cells are included into antibody-secreting 
cells (ASC). Nonetheless, plasma cells are the terminally differentiated B-cells, which 
lost the ability of proliferation (in contrast to plasmablasts) and the recognition of 
present antigens.  Plasma cells can be short or long lived. (E. Meint et al. 2006, M 
Duddy et al. 2007 ).  Short term plasma cells develop in lymphatic organs and they can 
be detected in circulation. 
 
It has been proven, that in around 90% -95% of MS patients present clonally expanded 
Ig secreting cells (Kabat et al. 1948). Ig production against autoantigens or foreign 
antigens (which cross-react with self-antigens) (Heather L Wilson et al. 2012) can 
preserved by different ways. This abnormality detected in CSF of MS patients and 
usually is based on B-lineage cells, precisely on antibody secreting cells, and are named 
oligoclonal bands (OCBs). This intrathecal Ig production create active ‘’spots’’ of 
inflammation in the CNS, which seem like lymphoid-like follicles (B cells follicles)( 
Markus Krumbholz et al. 2012, Heather Wilson et al.2012) . The prominent Ig in the 
OCBs typically is IgG isotype but IgM have also been tracked. (Heather L Wilson et al. 
2012 )   
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Regarding to the antibody dependent contribution of B cells in pathology of MS, first 
short-lived plasma cells (Ig producing cells) that are produced in secondary lymphoid 
organs pass the damaged BBB and they are gathered in the sites of inflammation in 
CNS (acute antigen response). Second, acute or chronic antigen activation cause the 
differentiation of memory B cells and the direct production of antibodies (antigen-
driven or non-antigen driven-T cell mediation). Third, long lived plasma cells provide 
mainly Ig production in the sites of inflammation. These long term plasma cells 
occasion OCBs, a hallmark of MS. Short-lived plasma cells become long lived in case 
that they find a survival niche (milieu) providing them essential factors for their 
development and survival. This B cell- fostering milieu basically is located in bone 
marrow. However, some of them there are also located in the sites of inflammation. 
This survival environment can achieved by production of BAFF, which is one survival 
factor produced by astrocytes and by secretion of chemokines, which induce the 
migration and survival of plasma cells in sites of inflammation. The main survival 
mediators of plasma cells are the chemokines and especially the homeostatic or 
lymphoid chemokines. This type of chemokines are vital for the maintenance and 
development of lymphoid organs. (Markus Krumbholz et al. 2012, Meint et al. 2006)  
Sometimes when are upregulated , they prompt B cell attracting in the site of 
inflammation but not directly like  inflammatory chemokines whose  main role is to 
direct immune cells to the inflammatory sites. Except of attracking their irrefutable 
role is the maintenance of B cells in these B cell follicles. Some known homeostatic 
chemokines are the CXCL12 and CXCL13, (Meint et al. 2006) and are produced by 
monocytes, macrophages, and dendritic cells (Carlsen HS et al. 2002, Krumbholz M et 
al. 2012) and are remarkably correlated with Ig production, the number of B cells and 
plasmablasts. Taken together, is proposed that the inflammatory CNS provides a B 
cells fostering environment, indicating that some B  lineage cells, ( long-lived plasma 
cells) can survive for a long term, sometimes even for a lifetime.  In this fostering 
environment is also included the intrathecal immunoglobulin (Ig)-producing cells.( 
Krumbholz M et al. 2012,  Meint et al. 2006) 
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After the first implication of the OCBs and their production of Igs in the MS pathology 
(Kabat et al. 1948), the role of Ig secreting cells and their produced antibodies became 
incontrovertible due to the abiding attempt of many researchers to clarify how 
antibodies are involved in the pathology of MS. In this effort attempted to identify 
their targets antibodies. Some findings implicated specific Abs for recognizing 
components of myelin sheath, promoting demyelination (, Wang and Fujinami 1997 , 
Van der Goes et al. 1999 ). Although their dominant appearance in OCBs of the CNS, 
that is a hallmark of MS diagnosis, it is still unclear their specific distribution. 
Particularly, it isn’t clear if they are implicated in the onset or in the progression of 
pathogenesis. (Klaus Lehmann Horn et al. 2013). Further evidence for the role of 
antibodies in pathology of MS indicates that the immune response, because of 
produced antibodies in the site of inflammation, may contribute to CNS demyelination 
(Breij et al. 2008, Merkler et al. 2006). According to some studies antibodies can’t 
trigger alone the onset of EAE in otherwise healthy animals, but they can deteriorate 
the CNS damage, pushing the progression of disease. (Benkhoucha et al. 2012).  Within 
plethora candidate myelin antigens, the most often implicated antibodies are the Abs 
to MOG (auto-antigen). While MOG is only a small “fraction” of myelin , its location 
(extracellular) makes prime and easily  accessible target for the attack of specific 
antibodies. (Gardinier et al. 1992, Lalive et al. 2011). Except of MOG have also been 
investigated the role of Abs recognizing PLP and MBP in EAE animal models ( Endoh et 
al. 1986 , van der Veen et al. 1986 ). An alternative but equally important role of Abs 
in an immune response is their capacity to recruit other cells in the sites of 
inflammation. Autoreactive T cells, monocytes and eosinophils are attracted to the 
sites of inflammation, resulting in the tissue damage.  
 
Beyond their role as producers of antibodies, earlier maturation stages and as well as 
memory B cells can act as antigen-presenting cells (APCs) or as antigens to other APCs. 
In general, APCs can divided to resident (CNS) and non-residence (bone marrow 
derived) APCs (Klaus Lehmann-Horn et al. 2011). Astrocytes and parenchymal 
microglia are belong to resident APCs (Fontana et al. 1984). In contrast, B cells, 
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macrophages, and dendritic cells participate among the non-resident APCs. 
Accordingly, professional APCs express in their surface MHC class II molecules, which 
in this context are recognized from T cells (TH1, TH17). The crosstalk among the T – 
and B cells, lead to activation of CD4+ T cell subsets and  may be also a ‘’key’’ in the 
pathology of autoimmune disorders. Dendritic cells are the professional APCs that can 
sufficiently by their own induce CNS autoimmunity (Greter et al. 2005). Among the 
rest APCs, B cells are the main APCs in the initiation of T cells response to protein 
antigens (Constant et al. 1999) and also in the activation of T cells in case of limited 
amount of antigens (Tejada-Simon MV et al. 2001).  
 
Besides, being a potent APC may contribute to the progress of inflammation by 
secreting pro- and anti- inflammatory Chemokines. Activated B cells produce 
substantial amounts of IL-6- proinflammatory chemokine, which is crucial for 
development of Th17 cells (Korn et al. 2008). A recent report supports that IL-6 
production by B cells is a major pathogenicity factor for B cells and that, in essence, B 
cells in MS contain a higher frequency of activated IL-6-producing subsets (Barr et al. 
2012). Except of B cells subsets, which contribute to the inflammation by secreting IL-
6, there are also B cell subtypes with anti-inflammatory properties. These B cells 
subsets may promote development of induced regulatory T cells with suppressive 
capacity. These regulatory B cells may further exert regulatory properties through 
provision of anti-inflammatory IL-10.  
 
All these activities of B cells summarize the complexity of B cell function in CNS 
autoimmune disease and highlight the possibility that unselective B cells directed 
therapeutic approaches may collaterally eradicate pre-existing B-cell regulation.   
Treatments of MS 
As described above, MS pathogenesis is likely more heterogeneous than previously 
thought. For that reason is very important to enrich the therapeutic armamentarium 
for the treatment of multiple sclerosis. Substantial interest has developed for testing 
B –cell depletion as a therapeutical strategy in MS because of the capacity of B cells to 
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act as potent APCs for activation of encephalitogenic T cells and to be developed into 
plasma cells secreting pathogenic antibodies. The target molecule is CD20, a surface 
molecule that well characterizes the B cell lineage. CD20 is expresses throughout B-
cell maturation starting from pre B cells up to memory B cells  and is only lost upon 
their terminal differentiation into plasma cells. Clinical trials of monoclonal antibodies 
against CD20 efficiently decrease circulating immature and mature B cells, but not the 
CD20-negative plasma cells. The positive effects of this drug associated with the 
reduction of B cells, which they serve as APCs and induce the inflammation. Contrary 
to the initial thought, the effectiveness of anti-CD20 is not derived from the reduction 
of Igs in many MS trials (antibody-independent activity) (Hauser et al. 2008).   
 
Natalizumab was the first monoclonal antibody approved as a DMT for relapsing MS. 
This drug targets the alpha-4 subunit of the VLA-4 receptor that is expressed on 
activated T cells and other mononuclear white blood cells. Normally VLA-4 interacts 
with vascular cell adhesion molecule 1 on endothelium and fibronectin in tissue, 
allowing cell adherence to the vessel wall and trafficking within tissues. Blocking VLA-
4 prevents inflammatory cell migration from the vasculature and within the CNS. 
(Bielekova B. et al. 2010) 
 
Figolimod (FTY720) has a unique mechanism of action among the drugs that are 
currently used in treatment of MS. FTY720 also interferes with lymphocyte migration, 
but it isn’t a monoclonal antibody like Natalizumab. This oral drug is an analog to 
sphingosine, binds to sphigosin-1-phosphate (S1P) receptors, being a superagonist 
that leads to internalization and following degradation of the receptors. This SP1 
stimulation is blocked, which is very important for immune-cell-trafficking (S.Mandala 
et al. 2002). Taken together, the main action of Fingolimod in the immune system is 
to regulate the trafficking of lymphocytes between primary and secondary lymphoid 
organs and circulating fluids (blood or lymphs). Fingolimod causes reversible 
lymphopenia without affecting lymphocyte proliferation or survival or cytokine 
production. This lymphopenia results from the retention of lymphocytes in secondary 
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lymphoid organs. However, this effect differs among immune cell populations even 
among the subtypes of them.  
Aim of the project  
Accordingly, the multiple sclerosis is one of the worse autoimmune diseases, affecting 
also young individuals. Thus, it is crucial the therapeutic processes to be improved, 
declaring the function of given drugs or investigating new ones. In our project, we 
studied the effects of certain drugs on leukocyte populations, especially, on B 
lymphocyte subsets in the blood of patients with MS. These drugs consist of 
Natalizumab and Fingolimod, which both inhibit migration of lymphocytes into the 
CNS. It seems that MS drugs differentially affect T and B lymphocytes responsiveness 
and may further allow to differentiate RRMS patients into B cell-dominant and T cell-
dominant patients. Moreover this analysis will take advantage of recent discoveries in 
lymphocyte differentiation and function and will include recently characterized 
terminally differentiated plasma cells and other B cell subsets which are central to the 
development of B cell-mediated autoimmunity, in contrast to the function of T cells 
subtypes TH17 (T helper 17 subtype) and TH9 (T helper 9 subtype), which are primarily 
involved in pathogenesis of auto-immune diseases. To determine whether each 
treatment induces alterations in distribution and function of peripheral B lymphocyte 
populations, identical analysis will be performed in patients with RRMS treated with 
Figolimod and Natalizumab. Finally this study could possibly help to identification and 
classification of B cell subpopulations of RRMS patients who influenced from 
Figolimod and Natalizumab treatment leading to improved condition of individuals.  
Materials and methods  
Study subjects 
A total of 18 patients presenting with RRMS (9 women, 9 men) were recruited in the 
study at department of neuroimmunology and Hertie Institute for brain research in, 
Tübingen Germany. At the time of admission, all patients had undergone brain and 
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spinal cord MRI and CSF analysis to detect oligoclonal bands. Blood samples were 
collected from the RRMS patients in period of 4 months. These patients were classified 
in 2 groups. The first group consists of 9 well-characterized RRMS patients who were 
treated with Fingolimod (MS-F: 9 patients). Venous blood samples from these patients 
were collected.  On the other hand, RRMS patients who were treated with 
Natalizumab belong to the second group (MS-N: 9 patients). For comparison there is 
a control group, which consists of healthy individuals (HI: 9 people). Patients with 
multiple sclerosis fulfilled the 2005 McDonald criteria for relapsing remitting or 
primary progressive multiple sclerosis. The written informed consent was obtained 
from each participant and the local ethics committee of Tübingen University approved 
the study.  
 
 MS-F                  MS-N      HP 
Number of participants     9 9       9 
female sex (%)   67% 
(6/9) 
55%  
(5/9) 
    33%  
   (3/9) 
Table1: Patients cohorts 
MS-F: Fingolimod-treated RRMS patients; MS-N: Natalizumab-treated RRMS patients; HP: 
healthy individuals  
Phenotypic analysis (PBMCs isolation- Cell staining - FACS analysis) 
A) PBMCS Isolation 
B) Sample preparation-Cell staining 
C) FACS analysis 
 
A total of 20-40 ml EDTA blood were obtained from RRMS patients and healthy 
donors. Peripheral mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque 
(Biochrom) density gradient centrifugation and multicolor flow cytometric analyses 
were performed. Calculated amount (100-250μl) of fresh EDTA blood were added to 
a round-bottom 96-well plate (BD Biosciences) in order to study circulating B-cells 
subsets. Before the cell staining Fc-blocker (human IgG,) were used throughout all 9 
wells to exclude unspecific antibody binding (25-50 μl depending on single or five color 
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staining). For all washing steps during the procedure of staining, 200μl phosphate-
buffered saline (PBS, Sigma Aldrich) supplemented with 2% fetal calf serum (FCS) – 
(FACS buffer) was added to each well. The plate was centrifuged at 1400 X g for 4 
minutes, and the supernatant was discarded. Specifically, for the cell staining the 
pellet was resuspended in 5 μl (single staining) and in 50 μl (Five color staining, 10 μl 
solution of each antibody) and incubated for 30 minutes at 4o C. After centrifugation 
and 2 washing steps in order to avoid unspecific binding, a secondary Ab for anti-IgM, 
anti-IgA, anti-IgG added and the cells incubated for another 30 minutes at 4° C. After 
the last washing steps the pellet was resuspended in 200μl FACS buffer for analysis 
with a flow cytometer (CyAnADP). The monoclonal antibodies, which were used for 
the cell staining : CD3 FITC, CD4 PE, CD4 APC, CD4 PB, CD4 APC-H7, CD27PE, CD20 APC-
H7, IgM APC, IgG APC, IgA APC (all provided by BD Biosciences), CD19 Pacific Blue 
(Biolegend) and  streptavidin (life technologies) which conjugates in the biotin of IgM, 
IgA and IgG. The secondary antidody is labeled with APC (Avidin Peroxidase Complex). 
Based on a SSC/CD19 gating (> 2500 CD19+ events), the above monoclonal anti-
human Abs were used to analyze the different B cell-subsets, although a precise 
definition of the latter population would require additional markers. The B cell subsets 
were defined as follows: naïve: CD27- , Memory: CD27+, Plasma cells: CD20- CD27+ 
(Catalina Lee Chang, et al 2010). The variability between FACS results of patients was 
analyzed with Dako Summit 4.2. Software.  
 
Flow cytometry is a powerful tool enabled by development of advanced flow 
cytometers. Robust assays can detect and monitor multiple analytes to produce a 
tremendous amount of data while conserving sample. Availability of different 
conjugates and putting the colors in the appropriate channels makes developing 
multicolor (>6) panels challenging. Data quality (results) depends greatly on proper 
panel design and optimization of instrument setup. In this study, was used a flow 
cytometer (CyAnADP) with three channels (488nm, 351nm, 635nm). Especially for the 
five color staining of human PBMCs, were used all the lasers. The term 
"compensation" as applied to flow cytometry typically refers to a mathematical 
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manipulation that subtracts or otherwise minimizes the effect of a spectral overlap 
across colors, thereby better resolving sub-populations, mainly using the same 
channel for two different colors. More accurately, compensation is the process by 
which the physical observation is mathematically manipulated to better observe 
biological significance. A common problem in resolving events that are positive in one 
color from events in another color is that the spectrum may be very close together. 
Worse yet, the spectrums may actually overlap. Thus, in assays that used 
clorochromes which are detected from the same channel, it is critical to undergo 
compensation between them. (e.g. FITC and PE, APC and APC-H7). 
 
A.            Uncompensated                            B.                      Compensated 
  
Figure 1: Compensation of clorochromes 
 A. single color staining: FITC against PE uncompensated. FITC and PE are two 
chlorochromes which are detected from the same laser (488 nm). B. FITC against APC 
compensated. In this case, parameter median should have difference less than 1.  One 
of the reasons these markers are used together is that each is adequately excited by 
a 488nm laser. For example, many flow cytometers have one or two lasers, but two or 
three detectors may exist on each laser path. If many fluorescence markers can be 
sufficiently excited by a single laser, but emitted in different wavelengths, they can be 
properly resolved on relatively inexpensive cytometers (because only one laser is 
needed for multiple markers). Below is the relative excitation efficiencies for FITC and 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 10:19:01 EET - 137.108.70.7
 BOULOGIANNI IOULIA            18 
 
PE, including a line identifying the commonly used 488nm laser line used to excite 
these markers. 
Statistical analysis  
Statistical analysis was performed using GraphPad Prism software. Data are presented 
as means ± SE. One-way ANOVA was used to compare the different groups. Student`s 
t-test was used to compare data from two different groups. A value of P<0.05 was 
considered as significant.  
Results  
Reduction of circulating transitional B cells in Fingolimod-treated 
RRMS patients compared to Natalizumab -treated and healthy 
individuals. 
Initially the population of circulating B cells in Fingolimod treated (MS-F) and 
Natalizumab treated patients (MS-N) was evaluated and compared with healthy 
controls. MS-F showed significantly lower amount of B cells in the circulation when 
they were compared to healthy individuals (P < 0.001). Natalizumab therapy could not 
change the frequency of B cell populations (P= 0.1969). The difference between the 
effect of Fingolimod and Natalizumab was also statistical significant (P < 0.001) (Fig. 
2.B). In this study we were not able to analyze the proportions of B lymphocyte subsets 
from untreated MS patients, thus the comparison with the group of untreated 
patients is only discussed based on data from the literature. In this case, MS-F had also 
fewer B cells than patients without any disease modifying drugs (Yusei Miyazaki et al. 
2014). The proportion of B cells was comparable between MS-N and untreated 
patients (Yusei Miyazaki et al. 2014, Kowarik et al. 2011).  
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 10:19:01 EET - 137.108.70.7
 BOULOGIANNI IOULIA            19 
 
CD3  
A.  
Gated on lymphocytes 
 
B.  
 
Figure 2: Fingolimod reduces and Natalizumab increases the number of B cells in the 
circulation (Differential effect of Fingolimod and Natalizumab on circulated B cells 
population) 
A. Gating strategy of B lymphocytes (CD19+). Representative dot blots from MS-F are 
shown. B. Proportions of B cells among total lymphocytes in MS-F, MS-N and healthy 
individuals (H). * MS-F significantly different compared to HP, P < 0.001. # Significantly 
different between MS-F and MS-N, P < 0.001. (MS-F significantly different compared 
to MS-N) 
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Distribution of B lymphocyte sub-populations (Naïve, Memory, 
Plasma ) of MS-F and MS-N.   
 
We next analyzed the distribution of B lymphocyte sub-populations in the inside of 
each group of patients (MS-F and MS-N) as well as in the control group (HP). Our 
results indicated that all three groups (MS-F, MS-N, HP) had higher proportion of naïve 
cells than memory cells.  
The periphery of healthy individuals is more enriched in plasma cells than periphery 
of patients. However, the difference among the groups of patients and healthy 
individual is not important (Fig3.A).The fraction of naïve B cells was larger in MS-F and 
MS-N in compared to HP. (Fig 3.B).  In addition, patients who received Natalizumab 
and Fingolimod drugs showed reduced percentage of memory cells (CD3- CD19+ 
CD27+ CD20+) when compared to healthy individual (Fig 3.C).        
 
A.                                                                         B. 
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C. 
 
Figure 3: Increased proportion of naïve B cells and reduced proportion of memory B 
cells among the total B cells in the circulation of RRMS patients 
A. Fractions of B cells subsets (naïve cells, memory cells, plasma cells) in fingolimod 
treated patients with MS (MS-F), B. natalizumab-treated patients with MS (MS-N) C. 
or healthy people (HP) in the peripheral blood.  
 
 
 MS-F MS-N HP 
NAÏVE CELLS 76.41% 82.56% 73.23% 
MEMORY CELLS 21.68% 18.98% 26.55% 
PLASMA CELLS 0.40% 0.21% 0.69% 
    
Table 2: B cell population percentages (%) in peripheral blood of patients with MS-F , 
MS-N and HP 
MS-F: Fingolimod-treated RRMS patients; MS-N: Natalizumab-treated RRMS patients; HP: 
healthy individuals  
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CD3   CD20 
Differential effects of Fingolimod and Natalizumab on B 
lymphocytes subtypes 
 
Thus based on total CD19+ cells (SSC/ CD19 gating), we analyzed the effect of different 
treatments on the proportions of circulating B cell subsets: memory cells (CD3- CD19+ 
CD27+ CD20+), naïve cells (CD3- CD19+ CD27-), plasma cells (CD3- CD19+ CD27+ CD20-
) (Fig4.A). As it is depicted in Fig 4.B, both Fingolimod and Natalizumab treatments 
significantly reduced the frequency of CD20-CD27+ plasma cells in comparison to 
healthy people, but this was more pronounced for Natalizumab treated patients (P< 
0.001). This difference between 2 therapies on the frequency of CD20-CD27+ plasma 
cells was statistically significant (P=0.0098). In contrast to CD20-CD27+ B cells, no 
major change was observed for the frequency of CD20+CD27+ B cells (Memory B cells) 
in the inside of CD3-CD19+ B lymphocytes after any therapy. There was a slight 
reduction in the percentage of memory B cells for Natalizumab treated patients, but 
this was not statistically significant (P> 0.05) (Fig 4.C).  There was also no remarkable 
change in the rate of CD27- B cells (Naïve B cells) in response to therapies (P> 0.05). 
There was an induction in the percentage of CD27- B cells in the patients with 
Natalizumab therapy, but this increase was not statistically noteworthy (Fig 4.D) 
 
 
A. 
Gated on lymphocytes                                     Gated on CD19+ cells  
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Figure 4: Differnent proportions of B cells subsets in the blood compartment of MS-F 
compared to MS-N 
A. Gating strategy of B cells (CD19+), naïve (CD27-), memory B cells (CD27+, CD20+) 
and plasma cells ( CD27+, CD20-) . Representative dot blots from MS-F are shown. B. 
Gating strategy of memory cells and proportions of plasma cells among total B cells in 
fingolimod-(MS-F) , natalizumab (MS-N)-treated patients and healthy people (HP). C. 
Gating strategy of naive cells and proportions of memory cells among total B cells in 
fingolimod-(MS-F) , natalizumab (MS-N)-treated patients and healthy people (HP). D.   
Gating strategy of naive cells and proportions of naïve cells among total B cells in 
fingolimod-(MS-F) , natalizumab (MS-N)-treated patients and healthy people (HP).  * 
Statistically significant different F and H, P < 0.001. & significantly different between 
N and H, P < 0.001. # significantly different between F and N, P < 0.001.  
 
Spontaneous Ig expression in different subsets of B cells (naïve, 
memory and plasma cells)  
 
We also evaluated the distribution of each membrane Ig in different subpopulation of 
B cells: Plasma cells (CD3- CD19+ CD27+CD20-), memory B cells (CD3- CD19+ CD27+ 
CD20+) and naïve B cells (CD3- CD19+ CD27-). We observed that the most prominent 
isotype of Ig in CD3- CD19+ CD27- B cells was the IgM (12 fold higher than IgG and IgA) 
(Fig5.A). Similar finding was also observed for CD3- CD19+ CD27+ CD20+ memory B 
cells, with IgM showing higher amount of induction compared to 2 other isotypes 
(Fig5.B). We must mention, however, the most abundant expressed isotype in the 
circulating plasma cells was IgA, which is mainly derived mucosal immune responses 
(Fig5.C) 
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A.                                                                 B. 
  
C .  
 
Figure 5: Spontaneous Ig expression in different subsets of B cells 
A. Proportions of membrane IgG, IgA and IgM in naïve cells of HP B. Proportions of 
membrane IgG, IgA and IgM in memory cells of Healthy people (HP) C. Proportions of 
membrane IgG, IgA and IgM in Plasma cells of HP (Healthy People).  
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Effect of Fingolimod and Natalizumab treatments on the frequency 
of Ig positive B cell subtypes   
 
Finally, we analyzed the effect of different therapies on the frequency of Ig positive B 
cell subtypes. As it is presented in figure 6 A-D, the was no significant effect of 
therapies (Fingolimod and Natalizumab) on the frequency of IgG+, IgM+, and IgA+ 
naïve B cells (P> 0.05).    
Similar to naïve B cells, both Fingolimod and Natalizumab therapies had no significant 
effect on the frequency of IgG+, IgA+ and IgM+ memory B cells (CD3- CD19+ CD27+ 
CD20+) compared to healthy people (Fig 7A-D). There was a slight induction in the 
percentage of IgG+ memory B cells in response to Fingolimod therapy but it was not 
remarkable (P> 0.05) (Fig 7.B). The slight reduction in the frequency of IgM+ CD3- 
CD19+ CD27+ CD20+ B cells in response to both Fingolimod and Natalizumab therapies 
was also not worthy (P> 0.05) (Fig 7D).    
As regard to other B cell subsets, plasma cells (CD3- CD19+ CD27+ CD20-) showed 
some changes in the production of Igs in response to different therapies (Fig 8.A). To 
begin with, while Natalizumab therapy significantly induced the frequency of IgG+ 
CD3- CD19+ CD27+ CD20- B cells, the Fingolimod treatment significantly reduced their 
frequency compared to healthy control (Fig 8.B). On the other hand, in response to 
both treatments, only Natalizumab treated patient showed a significant reduction in 
the frequency of IgA+ CD3- CD19+ CD27+ CD20- B cells (P=0.0228). Fingolimod treated 
patients appeared also a reduction in IgA+ CD3- CD19+ CD27+ CD20- B cells but it was 
not significant (P=0.1359). Although there was an increase in the frequency of IgM+ 
CD3- CD19+ CD27+ CD20- B cells in MS-F group compared to MS-N and healthy groups, 
but this induction was not significant (P=0.0525). No remarkable difference was 
pointed out between MS-N and HP groups for the percentage of IgM+ CD3-
CD19+CD20-CD27+ terminally differentiated B cells (Plasma Cells).  
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Figure 6: Ig membrane forms in Naïve B cells in MS-F compared to MS-N and HP 
A. Proportions of Ig membrane forms in naïve B cells (CD3- CD19+ CD27-) of MS-F, MS-
N and HP B. Proportion of IgG+ naïve cells among the naïve B cells (CD3- CD19+ CD27- 
IgG+) of MS-F, MS-N and HP C . Proportion of IgA+ naïve cells among the naïve B cells 
(CD3- CD19+ CD27- IgA+) of MS-F, MS-N and HP D. Proportion of IgM+ naïve cells 
among the naïve B cells (CD3- CD19+ CD27- IgM+) of MS-F, MS-N and HP. There was 
no significant difference in the percentage of IgG+, IgA+, IgM+ B naïve cells between 
3 different groups. The P value was greater than 0.05 (P> 0.05).  
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D. 
 
Figure 7: Ig membrane forms in Memory B cells in MS-F compared to MS-N and HP  
 A. Proportions of Ig membrane forms in memory B cells (CD3- CD19+ CD27+ CD20+) 
B cells of MS-F, MS-N and HP B. Proportion of IgG+ memory cells among the memory 
B cells (CD3- CD19+ CD27+ CD20+ IgG+) of MS-F , MS-N and HP C . Proportion of IgA+ 
memory cells among the memory B cells (CD3- CD19+ CD27+ CD20+ IgA+) of MS-F, 
MS-N and HP D. Proportion of IgM+ memory cells among the memory B cells (CD3- 
CD19+ CD27+ CD20+ IgM+) of MS-F, MS-N and HP. There was no significant difference 
in the percentage of IgG+, IgA+, IgM+ memory B cells between 3 different groups. The 
P value was greater than 0.05 (P> 0.05). 
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B.                                                                          C.  
 
 
D.  
Figure 8: Ig membrane forms in Plasma B cells in MS-F compared to MS-N and HP 
A. Proportions of Ig membrane forms in plasma B cells (CD3- CD19+ CD27+ CD20-) B 
cells of MS-F, MS-N and HP B .  Proportion of IgG+ plasma cells among the plasma B 
cells (CD3- CD19+ CD27+ CD20- IgG+) of MS-F, MS-N and HP C . Proportion of IgA+ 
plasma cells among the plasma B cells (CD3- CD19+ CD27+ CD20- IgA+) of MS-F, MS-N 
and HP D. Proportion of IgM+ plasma cells among the plasma B cells (CD3- CD19+ 
CD27+ CD20- IgM+) of MS-F, MS-N and HP. *Significantly different between F and N, 
P < 0.001. #significantly different between N and H, P < 0.001. No significant difference 
was shown between the 3 groups for the percentage of IgM+ plasma cells 
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Discussion 
The purpose of this study was to understand more about the impact of Fingolimod 
and Natalizumab treatments on the immune response within the blood compartment. 
In particular, we performed comparative studies on the effect of Fingolimod and 
Natalizumab on circulating B cells in patients with RRMS, with a focus on B cell 
subpopulations, antibody-dependent and antibody-independent activities.  
 
Fingolimod treatment significantly reduces the lymphocytes (M.C. Kowarik et. al 2011) 
and as described in this study, significantly reduces the circulating B cell fraction in the 
periphery. The proportion of B cells (CD19+) in Fingolimod-treated patients was 
profoundly reduced even compared to healthy individuals (HP). These findings are in 
agreement with the lymphopenia in the peripheral compartment (T Bohler et. al 2007, 
M.C. Kowarik et. al 2011), which is induced by this drug via its involvement in immune 
cell trafficking. The beneficial function of this drug is based on the property of 
lymphopenia in the peripheral blood. However, the effect of reduction of circulating 
B cells was less pronounced following Natalizumab treatment. B cell levels in 
peripheral blood were unchanged compared to HP. Moreover, beneficial therapeutic 
effect of Natalizumab might be related much more to the lower fraction of these cells 
in the CSF (M.C. Kowarik et. al 2011).  
 
It is proved that plasmablasts and memory cells are implicated for their crucial role in 
MS immune pathogenesis. Recent data indicates that also naïve B cells subsets might 
be involved in MS pathogenesis (M. Niino et. al 2009). In this survey, we focused on 
main circulating B-cell subsets: Memory B cells, Naïve B cells and Plasma cells. Mostly 
we investigated the impact of Fingolimod and Natalizumab treatments on peripheral 
blood with focus on the immune distribution in this compartment. Although MS 
treatments influence the proportions of B lymphocytes, the peripheral-B cell pool in 
patients groups is maintained. Furthermore a single B-cell subset appeared to be 
affected. The important finding in this study is the modified proportions of B cell 
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subtypes in the Fingolimod- and Natalizumab treated patients. Our findings 
highlighted that naïve B cells outnumber memory B cells in the blood of MS patients 
and healthy individuals in accordance with previous studies (C. Lee- Chang et. al 2010, 
M.C. Kowarik et. al 2011). Additional studies revealed that this effect is reversed in the 
CSF (C. Lee- Chang et. al 2010), while memory B cells outnumber naïve cells in this 
compartment. Last but not least memory B cells are reported to produce more pro-
inflammatory cytokines (e.g. TNFa) and less anti-inflammatory cytokines compared 
with naïve B Cells (M.Duddy et. al 2007).  
 
Concerning naive cells proportion, Fingolimod-treated patients showed no significant 
reduction in the periphery when compared with patients who were receiving 
Natalizumab treatment. The percentage of HP was also lower than MS patients. This 
implies that peripheral blood of patients consists of higher proportion of naïve cells, 
which have more anti-inflammatory properties, as a reflection to the inflammation 
due to the autoimmune disease. Furthermore, the results from the investigation of 
memory cells are in a line with the results from the naïve cells. Memory B cells were 
increased in the blood of HP compared to MS patients. In addition to, the CD27+ 
CD20+ B cells (memory) of Fingolimod- patients were more increased than 
Natalizumab-treated patients. Except of memory B cells, an important B cell 
subpopulation, which is profoundly implicated in MS due to its antibody-dependent 
participation, is the subset of plasmablasts. Patients who received Natalizumab (MS-
N) had significantly reduced percentage of plasmablasts in the peripheral blood when 
were compared to HP. However, we should t mention, that the levels of plasmablasts 
of MS-N were not remarkably lower than Fingolimod-treated patients.  
 
Our findings about the Fingolimod- and Natalizumab-induced alternation of B cell 
subsets and their contribution in immunity of MS, may be related with some recent 
studies. These studies suggest that B cells in general can be involved in immune 
regulation and particularly can contribute to MS pathogenesis through antibody-
independent activities (H.C von Budingen et. al 2011, C.T Harp et. al 2010). Some of 
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them are the induction of T cell responses via pro-nflammatory cytokines, the 
presentation of the CNS antigens and the supporting of migration of activated 
lymphocytes in CNS (H.C von Budingen et. al 2011, C.T Harp et. al 2010).  The B-cell 
mediated T cell activation, the presentation of antigens and the B cell clonal expansion 
are activities, which happen in the CNS and are mainly related with progress of 
inflammation. Except of the CNS and the site of inflammation, these activities can also 
take place in the peripheral lymphoid organs. The fate of activated lymphocytes in the 
periphery depend on production of chemokines by other immune cells.  
 
Thus, the reduction in percentage of secreted B cell subsets led to enhanced 
proportions of pro-inflammatory chemokines (plasma cells, memory B cells) and the 
increased proportions of B cell subsets with anti-inflammatory features, probably 
contribute to inhibition of proinflammatory activated B cells entering the CNS. In this 
sense, it came from the fact that chemokines and their receptors play an important 
role in establishing the distribution of lymphocyte populations in primary and 
secondary lymphoid tissues and in the recruitment of leukocytes to sites of 
inflammation. (Sallusto F et. al 1998). Reduced percentage of plasma cells and 
memory ones and enhanced proportions of naïve cells are observed in MS-N 
compared to MS-F. This can lead to prevention of further neuronal damage and 
progress of disease and could imply a therapeutic benefit of the Natalizumab 
treatment.  
 
Both chemokines, CXCL12 (SDF-1) and CXCL13 (BCA-1), regulate B cell migration in 
lymphoid tissues. In vitro human B cells migrate across the brain endothelium more 
rapidly than autologous T cells (Alter et al. 2003). These findings prove that there are 
differences in the migration of immune cells in the site of inflammation, based on 
different patterns of secreted chemokines.  Different patterns of them can influence 
the migration of single B cell subset among the other B cell subsets, too. Although the 
levels of its B cell subset as well as the exact chemokine profile and their influence in 
the migration of individual B cell subsets in different MS patients are important. 
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Accordingly, the phenomenal benefit of Natalizumab treatment could overlapped 
from the Fingolimod treatment, in case that the most abundant naive B cells have an 
advantage in migration in the site of inflammation.   
 
We also examined some anti-body dependent functions of these drugs in order to 
decide which treatment is properly designed for B-cell dominant MS patients. Previous 
studies have shown that long-lived plasma cells, originating from circulating 
plasmablasts or memory B cells, were able to survive in inflamed CNS and to induce 
the intrathecal synthesis of oligoclonal bands in MS (A. Corcione et. al 2004, S. Cepok 
et. al 2005). Plasma cells are the main B cell subtype, which implicated for their Ig 
production. Nevertheless, in this study we investigated the membrane bound form of 
Igs not only in circulating plasmablasts but also in other B cell subsets (Naïve and 
Memory B cells) in MS-N and MS-F patients. According to spontaneous expression of 
Igs of healthy individuals, we observed that the membrane Ig profile of naïve and 
memory B cells were not restricted to a specific isotype.  Nonetheless, the most 
prominent Ig was the IgM in both subsets, which is typically associated with them. 
These IgM+ B cell subtypes induce the secretion of natural antibodies of the IgM 
isotype. Such antibodies do not require somatic mutation or gene rearrangement. By 
contrast, IgA was the most abundantly expressing isotype in the surface of 
plasmablasts (Mei HE et. al 2009). It has been discovered that natural autoantibodies 
among these also natural antibodies are detected in the serum of healthy individuals, 
which contains immunoglobulins directed against surface molecules on 
oligodendrocytes.  
 
Naïve B cells are un-activated cells, which had not encountered antigen. These cells 
mostly present regulatory properties for the inflammation. Therefore, it is crucial to 
express a polyreactive Ig isotype in their surface and to produce natural Ig antibodies 
in the serum, in order to attack a plethora of foreign infectious or modified self -
antigens. The polyreactivity is a property belongs to IgM isotype. Last but not least, 
IgM is expressed as a transmembrane monomeric form in all naïve B cells. This 
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contrasts with serum IgA and IgG, which are present at significantly lower levels under 
the same conditions (free of antigens). IgA and IgG are isotypes stems from somatic 
mutation and gene rearrangement of IgM isotype and present high affinity to specific 
antigens.  
 
The proportions of IgM+, IgA+ and IgG+ naïve B cell subpopulations do not present 
major differences among the 3 groups. This implies, on the one hand that the 
proportions of IgM+, IgA+ and IgG+ naïve cells  alter after the Natalizumab and 
Fingolimod treatment and reach the values of naïve B cells of healthy individuals. On 
the other hand that the proportions of those B cell subsets are not affected from these 
treatments but they are not involved in the pathogenesis of MS through their 
antibody-dependent activities. So no differences between MS patients and healthy 
individuals ensue. In both hypotheses the affection refers to the migration of IgM+, 
IgA+ and IgM+ naïve B cell subsets and not in their proliferation.  
 
While naïve cells implicated in MS pathogenesis through indirect and regulatory 
responses, memory B cells and plasma cells are directly involved in the immune 
regulation of MS through antibody-dependent activities. Thus, the differences 
between the Ig+ B cell subsets among the 3 groups are more profound.   
 
Our data from IgM+ memory B cells indicate that,  this B cell subset of healthy 
individuals outnumber the same B cell subset of MS patients. These findings are 
supported by some studies in humans, which show a reduction in IgM in the blood of 
patients with systemic lupus erythematosus (Sle-autoimmune disease), which 
probably derived from the reduction in the IgM+ B cell subtypes. The decrease in sIgM 
may contribute to the increased number of apoptotic cells that are present in the 
peripheral blood of patients with Sle (Perniok A et al. 1998). Apoptotic cells express 
various autoantigens, and their persistence could generate harmful autoimmunity 
through the activation of self-reactive cells (Casciola Rosen et al. 1994). Natural IgM 
can bind to several autoantigens expressed by apoptotic cells, such as phospholipids, 
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thereby facilitating their clearance and preventing autoimmunity (Peng Y et al. 2005). 
In this case, we hypothesize that, the treatments (Fingolimod-Natalizumab) are not 
efficient to affect enough this B cell subset, providing clear therapeutical benefit. As a 
matter of fact, the examination of IgM+ plasma B cell subset indicated surprisingly 
unexpected differences among the groups. Despite the abundance of IgA+ plasma 
cells (typically associated with this subset), we observed that the IgM+ plasma cells of 
MS-F were unexpected higher than HP. This means, that this subpopulation is maybe 
affected by Fingolimod treatment, providing positive insights for this treatment’s 
benefit in specific B cell subpopulations. However, it is essential to note that IgM 
isotype had also implicated for participating in pro-inflammatory activities, whereas it 
had detected in Oligoclonal bands (OCBs) of active lessions.  
 
The IgA and IgG isostypes, as described above, are related with the high affinity 
recognition of foreign and self-antigens.  Especially IgG is the most prominent Ig 
isotype in the OCBs of the CNS, so it is reasonable to be elevated in MS patients. 
Therefore the efficiency of each treatment derived from its capacity to ameliorate the 
proportion of IgG+ B cells. IgG+ memory B cells of Fingolimod-treated patients were 
increased compared to HP and Natalizumab treatment. In spite of reduction of B cells 
and consequently the reduction of IgG+ memory B cell subset in periphery, 
fingolimod-treated patients tend to have more increased proportion of this B cells 
subset. On the other hand, Natalizumab treatment induced the reduction of IgG+ 
memory B cell compared to HP. Although these differences are not significant and 
there aren’t  results from untreated patients to compare, these findings seems to be 
related with the therapeutical benefits of treatments, improving our knowledge about 
their influence on specific B cell subsets, which are involved in the onset and progress 
of MS.  These results can be used as baseline for further studies in this research field 
as well. In the present work our outcomes showed that whereas IgG+ plasma cells are 
significantly reduced in MS-F . Natalizumab-treated patients pointed out comparable 
proportions of IgG+ plasma cells with HP. The IgG+ plasma cells of fingolimod patients 
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were 5-fold reduced even from HP. This might implies that Fingolimod treatment can 
inhibit the migration of this specific subpopulation in the periphery.  
 
To sum it up, we examined the IgA+ B cells subset among the groups of patients. IgA 
as previous described is an antibody isotype stems from class switching and present 
higher affinity to specific antigens and in case of auto-immunity, higher affinity to 
auto-antigens as well. Thus, the increased proportions of IgA in the periphery maybe 
contribute the disease worsen. Comparing the IgA+ memory B cells among the groups 
we did not observe profound differences in their proportions. On the other hand 
remarkable decrease in IgA+ plasma cells was observed. Mainly, this reduction 
belongs to MS-N patients compared to healthy individuals and Fingolimod-treated. 
This modified proportion of IgA+plasma cells of MS-N open the way for other 
researchers so as to estimate the therapeutical efficiency of Natalizumab in B-cell 
based MS. 
 
Although there are limitations in our study, due to the lack of data of untreated 
patients and lack of data of chemokine profiles of each group, the present study 
probably provides insights into the antibody-dependent and antibody-independent 
activities, which participate in the onset and progress of MS. In conclusion, such 
findings confirmed that these treatments alter the distribution of B cell subsets in the 
periphery, providing information for individual B cell-based MS treatments. However, 
in present work we can only hypothesize that there are differences in distribution of 
B cells subsets among the treatments, but the results are not significantly in order to 
decide which treatment is more efficient for B-cell based treatment. The aim of this 
study was to highlight the importance of B cells and especially of specific B cell subsets 
in the pathogenesis of MS. Many researchers can be based on such findings in order 
to investigate more treatments to find more suitable ones for B cell-based MS.  
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Perspectives  
On the whole, our data provided some insights into the contribution of B cell 
subpopulations in the MS pathogenesis. Further studies may result in the classification 
of new B cell subsets, which participate in pathogenic immune responses of Multiple 
sclerosis. Furthermore, these studies will provide more details about the properties of 
these cell subtypes. This discrepancy suggests that there might be different B cell 
subsets with regulatory and pathogenic properties. Such findings will extend our 
knowledge about the mechanisms of this demyelinating disease. Particularly, through 
the understanding of which immune cell subsets are involved in processes of MS 
pathogenesis. In this sense, this knowledge will help in the establishing of new 
effective treatments or in the improving of the existent ones. Perspective studies of 
the effects of drugs in immune cell subpopulations should be in accordance with  
chemotaxis assays, in which it will be assessed the lymphocyte migration due to some  
chemokines such :  CXCL13 (BCA) , CCL21 (SLC), CCL2 (MCP-1), CCL5 (RANTES) and 
CXCL12 and survival factors (BAFF). As a matter of fact, it may further be allowed to 
differentiate RRMS patients into B cell-dominant and T cell-dominant patients. This 
classification probably can ‘’give birth’’ in one developed individual treatment of 
autoimmune diseases, in which the side effects of treatments will be avoided. 
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